Orchid AMS eyes Rs 300 cr turnover in 3 years for antimicrobial resistance

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official.

Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs).

Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI.

"This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,